Compare Teradyne, Inc. (TER) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Twist Bioscience Corp — how do they compare? Teradyne, Inc. trades at $402.68 (market cap $62.34B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Teradyne, Inc. is far larger — about 6.2× Twist Bioscience Corp's market cap, and Teradyne, Inc. pays a 0.13% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and Twist Bioscience Corp for 27 Days on average.
| TER | TWST | |
|---|---|---|
Market Cap | $62.34B | $10.08B |
Volume | 3,368,404 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $483.84 | $205.00 |
52-Week Low | $132.05 | $25.45 |
Typical Hold Time | 37 Days | 27 Days |
Enterprise Value | $62.08B | $10.01B |
Dividend Yield | 0.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $398.72, down 3.17% on the day, but maintains a bullish technical outlook with strong support at $388 and resistance at $410. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.47 exceeding the $2.09 estimate. Revenue for 2025 reached $3.19 billion, and net income margin stands at 25.77%. Recent developments include the launch of the Magnum E2 memory test system and Iris 100 for microLED devices, targeting AI and high-performance computing demand.
The outlook for TER is positive, driven by AI-driven test equipment demand and consistent earnings outperformance. Risks include reliance on semiconductor cycles and competitive pressure from peers like KLAC. Analysts are bullish with a consensus price target of $461.50, representing a 15.7% upside from the current price. Institutional buying and a lack of sell ratings underscore confidence in growth prospects.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
